Network medicine for disease module identification and drug repurposing with the NeDRex platform.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
25 11 2021
25 11 2021
Historique:
received:
28
07
2021
accepted:
04
11
2021
entrez:
26
11
2021
pubmed:
27
11
2021
medline:
31
12
2021
Statut:
epublish
Résumé
Traditional drug discovery faces a severe efficacy crisis. Repurposing of registered drugs provides an alternative with lower costs and faster drug development timelines. However, the data necessary for the identification of disease modules, i.e. pathways and sub-networks describing the mechanisms of complex diseases which contain potential drug targets, are scattered across independent databases. Moreover, existing studies are limited to predictions for specific diseases or non-translational algorithmic approaches. There is an unmet need for adaptable tools allowing biomedical researchers to employ network-based drug repurposing approaches for their individual use cases. We close this gap with NeDRex, an integrative and interactive platform for network-based drug repurposing and disease module discovery. NeDRex integrates ten different data sources covering genes, drugs, drug targets, disease annotations, and their relationships. NeDRex allows for constructing heterogeneous biological networks, mining them for disease modules, prioritizing drugs targeting disease mechanisms, and statistical validation. We demonstrate the utility of NeDRex in five specific use-cases.
Identifiants
pubmed: 34824199
doi: 10.1038/s41467-021-27138-2
pii: 10.1038/s41467-021-27138-2
pmc: PMC8617287
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6848Informations de copyright
© 2021. The Author(s).
Références
Scannell, J. W., Blanckley, A., Boldon, H. & Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191–200 (2012).
pubmed: 22378269
doi: 10.1038/nrd3681
Ringel, M. S., Scannell, J. W., Baedeker, M. & Schulze, U. Breaking Eroom’s Law. Nat. Rev. Drug Discov. (2020) https://doi.org/10.1038/d41573-020-00059-3 .
Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41–58 (2019).
pubmed: 30310233
doi: 10.1038/nrd.2018.168
Park, K. A review of computational drug repurposing. Transl. Clin. Pharm. 27, 59–63 (2019).
doi: 10.12793/tcp.2019.27.2.59
Himmelstein, D. S. et al. Systematic integration of biomedical knowledge prioritizes drugs for repurposing. Elife 6, e26726 (2017).
Goh, K.-I. et al. The human disease network. Proc. Natl Acad. Sci. USA. 104, 8685–8690 (2007).
pubmed: 17502601
pmcid: 1885563
doi: 10.1073/pnas.0701361104
Menche, J. et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science 347, 1257601 (2015).
pubmed: 25700523
pmcid: 4435741
doi: 10.1126/science.1257601
Ghiassian, S. D., Menche, J. & Barabási, A.-L. A DIseAse MOdule Detection (DIAMOnD) algorithm derived from a systematic analysis of connectivity patterns of disease proteins in the human interactome. PLoS Comput. Biol. 11, e1004120 (2015).
pubmed: 25853560
pmcid: 4390154
doi: 10.1371/journal.pcbi.1004120
Sadegh, S. et al. Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing. Nat. Commun. 11, 3518 (2020).
pubmed: 32665542
pmcid: 7360763
doi: 10.1038/s41467-020-17189-2
Amberger, J. S., Bocchini, C. A., Scott, A. F. & Hamosh, A. OMIM.org: leveraging knowledge across phenotype-gene relationships. Nucleic Acids Res 47, D1038–D1043 (2019).
pubmed: 30445645
doi: 10.1093/nar/gky1151
Piñero, J. et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 48, D845–D855 (2020).
pubmed: 31680165
UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 47, D506–D515 (2019).
doi: 10.1093/nar/gky1049
Maglott, D., Ostell, J., Pruitt, K. D. & Tatusova, T. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res. 33, D54–D58 (2005).
pubmed: 15608257
doi: 10.1093/nar/gki031
Kotlyar, M., Pastrello, C., Malik, Z. & Jurisica, I. IID 2018 update: context-specific physical protein-protein interactions in human, model organisms and domesticated species. Nucleic Acids Res. 47, D581–D589 (2019).
pubmed: 30407591
doi: 10.1093/nar/gky1037
Mungall, C. J. et al. The Monarch Initiative: an integrative data and analytic platform connecting phenotypes to genotypes across species. Nucleic Acids Res 45, D712–D722 (2017).
pubmed: 27899636
doi: 10.1093/nar/gkw1128
Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074–D1082 (2018).
pubmed: 29126136
doi: 10.1093/nar/gkx1037
Jassal, B. et al. The reactome pathway knowledgebase. Nucleic Acids Res. 48, D498–D503 (2019).
pmcid: 7145712
Ursu, O. et al. DrugCentral 2018: an update. Nucleic Acids Res. 47, D963–D970 (2019).
pubmed: 30371892
doi: 10.1093/nar/gky963
Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
pubmed: 14597658
pmcid: 403769
doi: 10.1101/gr.1239303
Gyöngyi, Z., Garcia-Molina, H. & Pedersen, J. Combating Web Spam with TrustRank. Proceedings 2004 VLDB Conference 576–587 (2004) https://doi.org/10.1016/b978-012088469-8.50052-8 .
Lazareva, O. et al. BiCoN: Network-constrained biclustering of patients and omics data. Bioinformatics (2020) https://doi.org/10.1093/bioinformatics/btaa1076 .
Raudvere, U. et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 47, W191–W198 (2019).
pubmed: 31066453
pmcid: 6602461
doi: 10.1093/nar/gkz369
Kanehisa, M. et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res. 36, D480–D484 (2008).
pubmed: 18077471
doi: 10.1093/nar/gkm882
Fair, T. & Lonergan, P. The role of progesterone in oocyte acquisition of developmental competence. Reprod. Domest. Anim. 47, 142–147 (2012). Suppl 4.
pubmed: 22827363
doi: 10.1111/j.1439-0531.2012.02068.x
Hynes, N. E. & Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341–354 (2005).
pubmed: 15864276
doi: 10.1038/nrc1609
Bagnoli, M. et al. Choline metabolism alteration: a focus on ovarian cancer. Front. Oncol. 6, 153 (2016).
pubmed: 27446799
pmcid: 4916225
doi: 10.3389/fonc.2016.00153
Rosenzweig, A., Blenis, J. & Gomes, A. P. Beyond the Warburg effect: how do cancer cells regulate one-carbon metabolism? Front Cell Dev. Biol. 6, 90 (2018).
pubmed: 30159313
pmcid: 6103474
doi: 10.3389/fcell.2018.00090
Hopper-Borge, E. A. et al. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin. Ther. Targets 13, 339–362 (2009).
pubmed: 19236156
pmcid: 2670612
doi: 10.1517/14712590902735795
Matei, D., Chang, D. D. & Jeng, M. H. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor α and Akt inactivation. Clin. Cancer Res. 10, 681–690 (2004).
Apte, S. M., Bucana, C. D., Killion, J. J., Gershenson, D. M. & Fidler, I. J. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol. Oncol. 93, 78–86 (2004).
pubmed: 15047217
doi: 10.1016/j.ygyno.2003.12.041
Schmitt, J. & Matei, D. Platelet-derived growth factor pathway inhibitors in ovarian cancer. Clin. Ovarian Cancer Other Gynecol. Malig. 1, 120–126 (2008).
doi: 10.3816/COC.2008.n.013
Boctor, A. et al. Imatinib in refractory crohn disease: a series of 6 cases. Crohn’s Colitis 360, 1 (2019).
Can, G. et al. The Syk inhibitor fostamatinib decreases the severity of colonic mucosal damage in a rodent model of colitis. J. Crohns. Colitis 9, 907–917 (2015).
pubmed: 26116555
doi: 10.1093/ecco-jcc/jjv114
Tigno-Aranjuez, J. T., Asara, J. M. & Abbott, D. W. Inhibition of RIP2’s tyrosine kinase activity limits NOD2-driven cytokine responses. Genes Dev. 24, 2666–2677 (2010).
pubmed: 21123652
pmcid: 2994040
doi: 10.1101/gad.1964410
Overstreet, A. M. et al. The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis. Mucosal Immunol. 11, 1454–1465 (2018).
pubmed: 29988117
pmcid: 6162142
doi: 10.1038/s41385-018-0051-2
Stelzer, G. et al. The GeneCards suite: from gene data mining to disease genome sequence analyses. Curr. Protoc. Bioinforma. 54, 1.30.1–1.30.33 (2016).
doi: 10.1002/cpbi.5
Fay, W. P., Parker, A. C., Condrey, L. R. & Shapiro, A. D. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 90, 204–208 (1997).
pubmed: 9207454
doi: 10.1182/blood.V90.1.204.204_204_208
Jankun, J. et al. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis. Int. J. Mol. Med. 20, 683–687 (2007).
pubmed: 17912461
Hodges, A. et al. Regional and cellular gene expression changes in human Huntington’s disease brain. Hum. Mol. Genet 15, 965–977 (2006).
pubmed: 16467349
doi: 10.1093/hmg/ddl013
Jones, L. et al. Assessment of the relationship between pre-chip and post-chip quality measures for Affymetrix GeneChip expression data. BMC Bioinforma. 7, 211 (2006).
doi: 10.1186/1471-2105-7-211
Rabbani, G. H., Greenough, W. B. 3rd, Holmgren, J. & Lönnroth, I. Chlorpromazine reduces fluid-loss in cholera. Lancet 1, 410–412 (1979).
pubmed: 84263
doi: 10.1016/S0140-6736(79)90885-7
Beister, A. et al. The N-methyl-D-aspartate antagonist memantine retards progression of Huntington’s disease. J. Neural Transm. Suppl. 68, 117–122 (2004).
Shen, Y.-C. Lamotrigine in motor and mood symptoms of Huntington’s disease. World J. Biol. Psychiatry 9, 147–149 (2008).
pubmed: 17853293
doi: 10.1080/15622970701332520
Vattakatuchery, J. J. & Kurien, R. Acetylcholinesterase inhibitors in cognitive impairment in Huntington’s disease: A brief review. World J. Psychiatry 3, 62–64 (2013).
pubmed: 24255877
pmcid: 3832863
doi: 10.5498/wjp.v3.i3.62
Murray, T. F., Mpitsos, G. J., Siebenaller, J. F. & Barker, D. L. Stereoselective L-[3H]quinuclidinyl benzilate-binding sites in nervous tissue of Aplysia californica: evidence for muscarinic receptors. J. Neurosci. 5, 3184–3188 (1985).
pubmed: 4078624
pmcid: 6565233
doi: 10.1523/JNEUROSCI.05-12-03184.1985
Murdin, L., Hussain, K. & Schilder, A. G. M. Betahistine for symptoms of vertigo. Cochrane Database Syst. Rev. CD010696 (2016).
De Marchi, N., Daniele, F. & Ragone, M. A. Fluoxetine in the treatment of Huntington’s disease. Psychopharmacology 153, 264–266 (2001).
pubmed: 11205429
doi: 10.1007/s002130000575
Li, S. & Yang, J. Pitolisant for treating patients with narcolepsy. Expert Rev. Clin. Pharmacol. 13, 79–84 (2020).
pubmed: 31937172
doi: 10.1080/17512433.2020.1714435
Cummings, J., Lee, G., Ritter, A., Sabbagh, M. & Zhong, K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement. 5, 272–293 (2019).
doi: 10.1016/j.trci.2019.05.008
Wharton, W. et al. Rationale and design of the mechanistic potential of antihypertensives in preclinical Alzheimer’s (HEART) trial. J. Alzheimers Dis. 61, 815–824 (2018).
pubmed: 29254080
pmcid: 8933850
doi: 10.3233/JAD-161198
Davies, N. M., Kehoe, P. G., Ben-Shlomo, Y. & Martin, R. M. Associations of anti-hypertensive treatments with Alzheimer’s disease, vascular dementia, and other dementias. J. Alzheimers Dis. 26, 699–708 (2011).
pubmed: 21709373
doi: 10.3233/JAD-2011-110347
Li, N.-C. et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 340, b5465 (2010).
pubmed: 20068258
pmcid: 2806632
doi: 10.1136/bmj.b5465
Guimond, M.-O. & Gallo-Payet, N. The Angiotensin II type 2 receptor in brain functions: an update. Int. J. Hypertens. 2012, 351758 (2012).
pubmed: 23320146
pmcid: 3540774
doi: 10.1155/2012/351758
Butterfield, D. A. & Halliwell, B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat. Rev. Neurosci. 20, 148–160 (2019).
pubmed: 30737462
doi: 10.1038/s41583-019-0132-6
Kuehn, B. M. In Alzheimer research, glucose metabolism moves to center stage. JAMA 323, 297–299 (2020).
pubmed: 31913419
doi: 10.1001/jama.2019.20939
Yarchoan, M. & Arnold, S. E. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 63, 2253–2261 (2014).
pubmed: 24931035
pmcid: 4066335
doi: 10.2337/db14-0287
Claxton, A. et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s disease dementia. J. Alzheimers Dis. 44, 897–906 (2015).
pubmed: 25374101
doi: 10.3233/JAD-141791
Rosenbloom, M. H. et al. A phase II, single center, randomized, double‐blind, placebo‐controlled study of the safety and therapeutic effectiveness of intranasal glulisine in amnestic mild cognitive impairment and probable mild Alzheimer’s disease: Human/Human trials: Other. Alzheimers. Dement. 16, e036840 (2020).
Di Paolo, G. & Kim, T.-W. Linking lipids to Alzheimer’s disease: cholesterol and beyond. Nat. Rev. Neurosci. 12, 284–296 (2011).
pubmed: 21448224
pmcid: 3321383
doi: 10.1038/nrn3012
Masters, C. L. et al. Alzheimer’s disease. Nat. Rev. Dis. Prim. 1, 15056 (2015).
pubmed: 27188934
doi: 10.1038/nrdp.2015.56
Seddighi, S., Varma, V. & Thambisetty, M. α2-macroglobulin in Alzheimer’s disease: new roles for an old chaperone. Biomark. Med. 12, 311–314 (2018).
pubmed: 29537301
pmcid: 5967355
doi: 10.2217/bmm-2018-0027
Giri, M., Shah, A., Upreti, B. & Rai, J. C. Unraveling the genes implicated in Alzheimer’s disease. Biomed. Rep. 7, 105–114 (2017).
pubmed: 28781776
pmcid: 5526178
doi: 10.3892/br.2017.927
Chandra, S. & Pahan, K. Gemfibrozil, a lipid-lowering drug, lowers amyloid plaque pathology and enhances memory in a mouse model of Alzheimer’s disease via peroxisome proliferator-activated receptor α. J. Alzheimers Dis. Rep. 3, 149–168 (2019).
pubmed: 31259309
pmcid: 6597963
doi: 10.3233/ADR-190104
Stibius, K. B. & Sneppen, K. Modeling the two-hybrid detector: experimental bias on protein interaction networks. Biophys. J. 93, 2562–2566 (2007).
pubmed: 17557786
pmcid: 1965432
doi: 10.1529/biophysj.106.098236
Schaefer, M. H., Serrano, L. & Andrade-Navarro, M. A. Correcting for the study bias associated with protein-protein interaction measurements reveals differences between protein degree distributions from different cancer types. Front. Genet. 6, 260 (2015).
pubmed: 26300911
pmcid: 4523822
doi: 10.3389/fgene.2015.00260
Brown, A. S. & Patel, C. J. A standard database for drug repositioning. Sci. Data 4, 170029 (2017).
pubmed: 28291243
pmcid: 5349249
doi: 10.1038/sdata.2017.29
Kou, L., Markowsky, G. & Berman, L. A fast algorithm for Steiner trees. Acta Inf. 15, 141–145 (1981).
doi: 10.1007/BF00288961
Järvelin, K. & Kekäläinen, J. Cumulated gain-based evaluation of IR techniques. ACM Trans. Inf. Syst. Secur. 20, 422–446 (2002).
doi: 10.1145/582415.582418